Clinical Characterization of FGFR-Altered Pediatric Low-Grade Gliomas

Area of Science:

• Pediatric oncology
• Neuro-oncology
• Molecular biology

Background:

• Pediatric low-grade gliomas (pLGG) are the most common childhood central nervous system tumors.
• While BRAF alterations are frequent drivers, a subset of pLGGs harbor activating mutations or fusions in Fibroblast Growth Factor Receptor 1/2/3 (FGFR1/2/3).
• FGFR signaling is critical for cell growth and survival, interacting with key pathways like RAS/MAPK, PI3K/AKT, and JAK/STAT.

Purpose of the Study:

• To characterize the epidemiology, molecular, radiographic, and histologic features of FGFR-altered pLGGs.
• To define the clinical course and outcomes for patients with FGFR-altered pLGGs.
• To explore therapeutic implications and current/emerging treatment strategies for pediatric FGFR-altered gliomas.

Main Methods:

• Retrospective analysis of a cohort of pediatric patients with FGFR-altered pLGGs.
• Comprehensive review of epidemiologic, molecular, radiographic, and histologic data.
• Evaluation of clinical outcomes and treatment responses.

Main Results:

• Detailed description of the patient cohort with FGFR-altered pLGGs.
• Identification of specific molecular alterations and their correlation with tumor characteristics.
• Analysis of treatment efficacy and clinical trajectories in this subgroup.

Conclusions:

• FGFR alterations represent a distinct molecular subgroup within pediatric low-grade gliomas.
• Understanding these alterations is crucial for defining clinical behavior and therapeutic strategies.
• Targeted therapies hold promise for improving outcomes in pediatric patients with FGFR-altered gliomas.